BRPI0818191A2 - métodos para a formação de vasos a partir de uma população de células de perfusato placentário e para o tratamento de um indivíduo tendo uma doença cardíaca ou vascular, distúrbio, condição ou insulficência - Google Patents

métodos para a formação de vasos a partir de uma população de células de perfusato placentário e para o tratamento de um indivíduo tendo uma doença cardíaca ou vascular, distúrbio, condição ou insulficência

Info

Publication number: BRPI0818191A2
Authority: BR; Brazil
Prior art keywords: insulin; vessels; disorder; heart; individual
Prior art date: 2007-09-26

Application number

BRPI0818191A

Other languages

English (en)

Inventor

Rendon Barrigan Henry

Kang Lin

A Heidaran Mohammad

A Voskinarian-Berse Vanessa

Zhang Xiaokui

Original Assignee

Celgene Cellular Therapeutics

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-26

Filing date

2008-09-26

Publication date

2017-06-13

2008-09-26 Application filed by Celgene Cellular Therapeutics filed Critical Celgene Cellular Therapeutics

2017-06-13 Publication of BRPI0818191A2 publication Critical patent/BRPI0818191A2/pt

2017-10-03 Publication of BRPI0818191A8 publication Critical patent/BRPI0818191A8/pt

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
230000015572 biosynthetic process Effects 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
208000035475 disorder Diseases 0.000 title 1
208000019622 heart disease Diseases 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
230000003169 placental effect Effects 0.000 title 1
208000019553 vascular disease Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0692—Stem cells; Progenitor cells; Precursor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Immunology (AREA)
Virology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0818191A 2007-09-26 2008-09-26 Métodos para a formação de vasos a partir de uma população de células de perfusado placentário, e, uso de uma população de células de perfusado placentário e de perfusado placentário humano ou células de perfusado placentário humano BRPI0818191A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US99567907P	2007-09-26	2007-09-26
PCT/US2008/011167 WO2009042201A1 (en)	2007-09-26	2008-09-26	Angiogenic cells from human placental perfusate

Publications (2)

Publication Number	Publication Date
BRPI0818191A2 true BRPI0818191A2 (pt)	2017-06-13
BRPI0818191A8 BRPI0818191A8 (pt)	2017-10-03

Family

ID=40043062

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0818191A BRPI0818191A8 (pt)	2007-09-26	2008-09-26	Métodos para a formação de vasos a partir de uma população de células de perfusado placentário, e, uso de uma população de células de perfusado placentário e de perfusado placentário humano ou células de perfusado placentário humano

Country Status (12)

Country	Link
US (1)	US20090104164A1 (pt)
EP (1)	EP2205719A1 (pt)
JP (6)	JP5703493B2 (pt)
KR (9)	KR20220122774A (pt)
CN (1)	CN101978045A (pt)
AU (1)	AU2008305516A1 (pt)
BR (1)	BRPI0818191A8 (pt)
CA (1)	CA2700613C (pt)
IL (4)	IL204762A0 (pt)
MX (1)	MX2010003217A (pt)
RU (1)	RU2010116271A (pt)
WO (1)	WO2009042201A1 (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1349918T3 (da)	2000-12-06	2014-11-10	Anthrogenesis Corp	Fremgangsmåde til indsamling af stamceller fra moderkagen
US7311905B2 (en) *	2002-02-13	2007-12-25	Anthrogenesis Corporation	Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20080152629A1 (en) *	2000-12-06	2008-06-26	James Edinger	Placental stem cell populations
US7311904B2 (en)	2001-02-14	2007-12-25	Anthrogenesis Corporation	Tissue matrices comprising placental stem cells, and methods of making the same
US7498171B2 (en) *	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
JP2006509770A (ja) *	2002-11-26	2006-03-23	アンソロジェネシスコーポレーション	細胞治療学、細胞治療単位、およびそれらを利用した治療法
GB0321337D0 (en) *	2003-09-11	2003-10-15	Massone Mobile Advertising Sys	Method and system for distributing advertisements
JP2007531116A (ja) *	2004-03-26	2007-11-01	セルジーン・コーポレーション	幹細胞バンクを提供するためのシステム及び方法
AU2006304274B2 (en) *	2005-10-13	2012-08-16	Celularity Inc.	Production of oligodendrocytes from placenta-derived stem cells
AU2006304277B2 (en)	2005-10-13	2012-07-05	Celularity Inc.	Immunomodulation using placental stem cells
US8455250B2 (en) *	2005-12-29	2013-06-04	Anthrogenesis Corporation	Co-culture of placental stem cells and stem cells from a second source
EP1974013A2 (en)	2005-12-29	2008-10-01	Anthrogenesis Corporation	Improved composition for collecting and preserving placental stem cells and methods of using the composition
ES2671355T3 (es)	2005-12-29	2018-06-06	Anthrogenesis Corporation	Poblaciones de células madre placentarias
US7993918B2 (en)	2006-08-04	2011-08-09	Anthrogenesis Corporation	Tumor suppression using placental stem cells
ZA200902233B (en)	2006-10-23	2010-07-28	Anthrogenesis Corp	Methods and compositions for treatment of bone defects with placental cell populations
EP2129775A1 (en) *	2007-02-12	2009-12-09	Anthrogenesis Corporation	Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
SI2120977T1 (sl)	2007-02-12	2014-01-31	Anthrogenesis Coroporation	Zdravljenje vnetnih bolezni z uporabo placentarnih matičnih celic
US9200253B1 (en)	2007-08-06	2015-12-01	Anthrogenesis Corporation	Method of producing erythrocytes
KR20220122774A (ko) *	2007-09-26	2022-09-02	셀룰래리티 인코포레이티드	인간 태반 관류액으로부터의 혈관형성 세포
RS53841B1 (sr)	2007-09-28	2015-06-30	Anthrogenesis Corporation	Supresija tumora korišćenjem humanog placentalnog perfuzata i intermedijernih ćelija ubica poreklom iz humane placente
DK2330889T3 (en)	2008-08-20	2017-01-30	Anthrogenesis Corp	Improved cell composition and process for making the same
KR20180108887A (ko) *	2008-08-20	2018-10-04	안트로제네시스 코포레이션	단리된 태반 세포를 사용한 뇌졸중 치료
MX2011001992A (es)	2008-08-22	2011-03-29	Anthrogenesis Corp	Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
CA2743566C (en)	2008-11-19	2021-11-09	Anthrogenesis Corporation	Amnion derived adherent cells
AR077369A1 (es)	2009-07-02	2011-08-24	Anthrogenesis Corp	Metodopara producir eritrocitos sin celulas alimentadoras
US9163212B2 (en)	2010-01-25	2015-10-20	Warsaw Orthopedic, Inc.	Osteogenic cell delivery matrix
WO2011094181A1 (en)	2010-01-26	2011-08-04	Anthrogenesis Corporation	Treatment of bone-related cancers using placental stem cells
US20110212065A1 (en) *	2010-02-18	2011-09-01	Timothy Jansen	Methods of manufacture of therapeutic products comprising vitalized placental dispersions
SI2556145T1 (sl)	2010-04-07	2017-01-31	Anthrogenesis Corporation	Angiogeneza z uporabo placentnih matičnih celic
AU2011237743A1 (en)	2010-04-08	2012-11-01	Anthrogenesis Corporation	Treatment of sarcoidosis using placental stem cells
US9352003B1 (en)	2010-05-14	2016-05-31	Musculoskeletal Transplant Foundation	Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en)	2010-05-14	2014-11-11	Musculoskeletal Transplant Foundation	Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en)	2010-05-14	2018-11-20	Musculoskeletal Transplant Foundation	Tissue-derived tissuegenic implants, and methods of fabricating and using same
CN107828727A (zh)	2010-07-13	2018-03-23	人类起源公司	产生自然杀伤细胞的方法、由此获得的细胞群体及其用途
RU2435594C1 (ru) *	2010-10-04	2011-12-10	Федеральное Государственное Учреждение Ростовский научно-исследовательский институт акушерства и педиатрии Федерального агентства по высокотехнологичной медицинской помощи	Способ лечения плацентарной недостаточности во ii-iii триместрах беременности
AR093183A1 (es)	2010-12-31	2015-05-27	Anthrogenesis Corp	Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
EP3443968A1 (en)	2011-06-01	2019-02-20	Celularity, Inc.	Treatment of pain using placental stem cells
WO2013055476A1 (en)	2011-09-09	2013-04-18	Anthrogenesis Corporation	Treatment of amyotrophic lateral sclerosis using placental stem cells
AU2013204922B2 (en)	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
AU2014215458A1 (en)	2013-02-05	2015-08-13	Anthrogenesis Corporation	Natural killer cells from placenta
EP3613847A1 (en)	2013-03-13	2020-02-26	The University of Queensland	A method of isolating cells for therapy and prophylaxis
JP6493692B2 (ja)	2013-03-15	2019-04-10	セルジーンコーポレイション	修飾されたｔリンパ球
US9821013B2 (en)	2013-04-02	2017-11-21	University Of Florida Research Foundation, Inc.	Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators
RU2016123361A (ru)	2013-11-15	2017-12-20	Антродженезис Корпорейшн	Композиции, включающие клетки плацентарного перфузата человека
CN103756965B (zh) *	2014-01-27	2016-04-06	山东省齐鲁干细胞工程有限公司	一种从胎盘中灌洗造血干细胞的方法
CN104152405B (zh) *	2014-08-15	2016-06-29	博雅干细胞科技有限公司	从胎盘中分离提取造血干细胞的方法
CA3177726A1 (en)	2015-05-21	2016-11-24	Musculoskeletal Transplant Foundation	Modified demineralized cortical bone fibers
WO2017014561A1 (ko) *	2015-07-20	2017-01-26	가톨릭대학교 산학협력단	제대혈 ｃｄ３４ 양성 세포에서 골수유래억제세포로의 분화 유도 및 증식 방법, 및 상기 골수유래억제세포의 용도
JP6648259B2 (ja) *	2015-08-12	2020-02-14	チャバイオテックカンパニーリミテッド	向上された臍帯由来付着型幹細胞、その製造方法及びその用途
US12551509B2 (en)	2015-11-18	2026-02-17	Lucina Patent Holdco, Llc	Acellular regenerative products and methods of their manufacture
EP3548051A1 (en) *	2016-12-05	2019-10-09	Celularity, Inc.	Treatment of lymphedema and related conditions using placental adherent cells
CN107058224B (zh) *	2017-02-10	2020-08-21	广东唯泰生物科技有限公司	一种以胎盘为来源的造血干细胞提取及冻存方法
EP3887508A1 (en)	2018-11-30	2021-10-06	Celularity Inc.	Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
CN109652372A (zh) *	2019-01-09	2019-04-19	陕西九州细胞基因工程有限公司	一种人胎盘组织源造血干细胞的快速分离、制备方法
JP6977969B2 (ja) *	2019-03-22	2021-12-08	株式会社ガイアバイオメディシン	免疫細胞提供システム
WO2020252464A1 (en)	2019-06-14	2020-12-17	Celularity Inc.	Populations of natural killer cells for treating cancers
US20220273716A1 (en)	2019-07-25	2022-09-01	Celularity Inc.	Populations of natural killer cells comprising a cd38 chimeric antigen receptor
WO2021022229A1 (en)	2019-07-31	2021-02-04	Celularity Inc.	Populations of natural killer cells comprising a cleavage resistant cd16
WO2021113849A1 (en)	2019-12-05	2021-06-10	Celularity Inc.	Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16
US20220000919A1 (en)	2020-01-29	2022-01-06	Celularity Inc.	Placental derived natural killer cells for treatment of coronavirus infections
WO2023278628A1 (en)	2021-06-29	2023-01-05	Celularity Inc.	Human placental hematopoietic stem cell derived natural killer cells in acute myeloid leukemia (aml) remission with minimal residual disease (mrd) or relapsed/refractory aml
CR20240104A (es)	2021-07-29	2024-06-28	Celularity Inc	Células NK derivadas de la placenta como senolítico para usos terapéuticos y otros.
EP4463474A1 (en)	2022-01-11	2024-11-20	Celularity Inc.	Cleavage resistant cd16 constructs and uses thereof

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3862002A (en) *	1962-05-08	1975-01-21	Sanfar Lab Inc	Production of physiologically active placental substances
US5863531A (en) *	1986-04-18	1999-01-26	Advanced Tissue Sciences, Inc.	In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5192553A (en) *	1987-11-12	1993-03-09	Biocyte Corporation	Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5004681B1 (en) *	1987-11-12	2000-04-11	Biocyte Corp	Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5605822A (en) *	1989-06-15	1997-02-25	The Regents Of The University Of Michigan	Methods, compositions and devices for growing human hematopoietic cells
US5464764A (en) *	1989-08-22	1995-11-07	University Of Utah Research Foundation	Positive-negative selection methods and vectors
US5061620A (en) *	1990-03-30	1991-10-29	Systemix, Inc.	Human hematopoietic stem cell
US5486359A (en) *	1990-11-16	1996-01-23	Osiris Therapeutics, Inc.	Human mesenchymal stem cells
US6010696A (en) *	1990-11-16	2000-01-04	Osiris Therapeutics, Inc.	Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5733542A (en) *	1990-11-16	1998-03-31	Haynesworth; Stephen E.	Enhancing bone marrow engraftment using MSCS
US5197985A (en) *	1990-11-16	1993-03-30	Caplan Arnold I	Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
ATE225370T1 (de) *	1993-03-31	2002-10-15	Pro Neuron Inc	Inhibitor der stammzellproliferation und seine verwendung
US5709854A (en) *	1993-04-30	1998-01-20	Massachusetts Institute Of Technology	Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5591625A (en) *	1993-11-24	1997-01-07	Case Western Reserve University	Transduced mesenchymal stem cells
US6288030B1 (en) *	1993-12-22	2001-09-11	Amgen Inc.	Stem cell factor formulations and methods
CA2192103C (en) *	1994-06-06	2002-02-05	Arnold I. Caplan	Biomatrix for tissue regeneration
US6174333B1 (en) *	1994-06-06	2001-01-16	Osiris Therapeutics, Inc.	Biomatrix for soft tissue regeneration using mesenchymal stem cells
US6103522A (en) *	1994-07-20	2000-08-15	Fred Hutchinson Cancer Research Center	Human marrow stromal cell lines which sustain hematopoiesis
US5874301A (en) *	1994-11-21	1999-02-23	National Jewish Center For Immunology And Respiratory Medicine	Embryonic cell populations and methods to isolate such populations
US5736396A (en) *	1995-01-24	1998-04-07	Case Western Reserve University	Lineage-directed induction of human mesenchymal stem cell differentiation
US5695998A (en) *	1995-02-10	1997-12-09	Purdue Research Foundation	Submucosa as a growth substrate for islet cells
US6011000A (en) *	1995-03-03	2000-01-04	Perrine; Susan P.	Compositions for the treatment of blood disorders
US5716616A (en) *	1995-03-28	1998-02-10	Thomas Jefferson University	Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US5733541A (en) *	1995-04-21	1998-03-31	The Regent Of The University Of Michigan	Hematopoietic cells: compositions and methods
US5925567A (en) *	1995-05-19	1999-07-20	T. Breeders, Inc.	Selective expansion of target cell populations
US5877299A (en) *	1995-06-16	1999-03-02	Stemcell Technologies Inc.	Methods for preparing enriched human hematopoietic cell preparations
US5858782A (en) *	1995-11-13	1999-01-12	Regents Of The University Of Michigan	Functional human hematopoietic cells
US6337387B1 (en) *	1995-11-17	2002-01-08	Asahi Kasei Kabushiki Kaisha	Differentiation-suppressive polypeptide
US5716794A (en) *	1996-03-29	1998-02-10	Xybernaut Corporation	Celiac antigen
CA2251983C (en) *	1996-04-19	2003-12-16	Sudhakar Kadiyala	Regeneration and augmentation of bone using mesenchymal stem cells
US5919176A (en) *	1996-05-14	1999-07-06	Children's Hospital Medical Center Of Northern California	Apparatus and method for collecting blood from an umbilical cord
US5827740A (en) *	1996-07-30	1998-10-27	Osiris Therapeutics, Inc.	Adipogenic differentiation of human mesenchymal stem cells
US5916202A (en) *	1996-08-30	1999-06-29	Haswell; John N.	Umbilical cord blood collection
US6335195B1 (en) *	1997-01-28	2002-01-01	Maret Corporation	Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US5879318A (en) *	1997-08-18	1999-03-09	Npbi International B.V.	Method of and closed system for collecting and processing umbilical cord blood
AU9127098A (en) *	1997-09-04	1999-03-22	Osiris Therapeutics, Inc.	Ligands that modulate differentiation of mesenchymal stem cells
PT1062321E (pt) *	1998-03-13	2005-05-31	Osiris Therapeutics Inc	Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
JP4526186B2 (ja) *	1998-06-08	2010-08-18	オシリスセラピューティクス，インコーポレイテッド	造血幹細胞を試験管内で維持する方法と組成物
US6184035B1 (en) *	1998-11-18	2001-02-06	California Institute Of Technology	Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
JP3089299B2 (ja) *	1998-12-14	2000-09-18	京都大学長	生体内に毛細血管が豊富な組織を作成するのに用いる新生血管床形成用用具
MXPA01007820A (es) *	1999-02-04	2003-06-19	Technion Res & Dev Foundation	Metodo y aparato para mantenimiento y expansion de celulas de tallo hemopoyeticas y/o celulas progenitoras.
FR2792202B1 (fr) *	1999-04-19	2003-06-13	Pharmascience Lab	Extrait peptidique de lupin et composition pharmaceutique ou cosmetique ou nutraceutique comprenant un tel extrait
US8075881B2 (en) *	1999-08-05	2011-12-13	Regents Of The University Of Minnesota	Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US6685936B2 (en) *	1999-10-12	2004-02-03	Osiris Therapeutics, Inc.	Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US20050009876A1 (en) *	2000-07-31	2005-01-13	Bhagwat Shripad S.	Indazole compounds, compositions thereof and methods of treatment therewith
DK1349918T3 (da) *	2000-12-06	2014-11-10	Anthrogenesis Corp	Fremgangsmåde til indsamling af stamceller fra moderkagen
US7311904B2 (en) *	2001-02-14	2007-12-25	Anthrogenesis Corporation	Tissue matrices comprising placental stem cells, and methods of making the same
US7311905B2 (en) *	2002-02-13	2007-12-25	Anthrogenesis Corporation	Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20030045552A1 (en) *	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
IL157350A0 (en) *	2001-02-14	2004-02-19	Anthrogenesis Corp	Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030044977A1 (en) *	2001-08-10	2003-03-06	Norio Sakuragawa	Human stem cells originated from human amniotic mesenchymal cell layer
US20040018178A1 (en) *	2002-01-22	2004-01-29	Advanced Cell Technology	Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis
AU2003216286B2 (en) *	2002-02-13	2008-08-28	Celularity Inc.	Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
GB0205867D0 (en) *	2002-03-13	2002-04-24	Univ Nottingham	Polymer composite loaded with functioning matter
US20030187515A1 (en) *	2002-03-26	2003-10-02	Hariri Robert J.	Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) *	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CA2488013A1 (en) *	2002-05-30	2003-12-11	Celgene Corporation	Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes
US7422736B2 (en) *	2002-07-26	2008-09-09	Food Industry Research And Development Institute	Somatic pluripotent cells
JP4480128B2 (ja) *	2002-11-20	2010-06-16	独立行政法人科学技術振興機構	マトリックスメタロプロテアーゼ−９の産生を阻害するための薬剤
JP2006517975A (ja) *	2003-02-13	2006-08-03	アンスロジェネシスコーポレーション	疾患、障害または症状を患っている個体を治療するための臍帯血の使用
ES2552226T3 (es) *	2003-06-27	2015-11-26	DePuy Synthes Products, Inc.	Reparación y regeneración de cartílago y hueso utilizando células derivadas posparto
US7569385B2 (en) *	2003-08-14	2009-08-04	The Regents Of The University Of California	Multipotent amniotic fetal stem cells
AR046123A1 (es) *	2003-10-17	2005-11-23	Crc For Innovative Dairy Produ	Aislamiento de celulas simil-celulas madre, uso de las mismas
WO2005063807A2 (en) *	2003-12-29	2005-07-14	Centelion	Treatment of coronary or peripheral ischemia
CA2565972A1 (en) *	2004-06-15	2005-12-29	Baxter International Inc.	Ex-vivo application of solid microparticulate therapeutic agents
US7909806B2 (en) *	2004-09-23	2011-03-22	Anthrogenesis Corporation	Cord blood and placenta collection kit
US7147626B2 (en) *	2004-09-23	2006-12-12	Celgene Corporation	Cord blood and placenta collection kit
US8017395B2 (en) *	2004-12-17	2011-09-13	Lifescan, Inc.	Seeding cells on porous supports
AU2006203990B2 (en) *	2005-01-07	2011-08-11	Wake Forest University Health Sciences	Regeneration of pancreatic islets by amniotic fluid stem cell therapy
US7642091B2 (en) *	2005-02-24	2010-01-05	Jau-Nan Lee	Human trophoblast stem cells and use thereof
US20060222634A1 (en) *	2005-03-31	2006-10-05	Clarke Diana L	Amnion-derived cell compositions, methods of making and uses thereof
ES2654428T3 (es) *	2005-04-12	2018-02-13	Mesoblast, Inc.	Aislamiento de células multipotenciales adultas por fosfatasa alcalina no específica de tejido
KR20080031735A (ko) *	2005-06-10	2008-04-10	셀진 코포레이션	인간 태반 콜라겐 조성물, 그의 제조 방법, 그의 사용 방법및 상기 조성물을 포함하는 키트
US20070038298A1 (en) *	2005-06-30	2007-02-15	Sulner Joseph W	Repair of tympanic membrane using placenta derived collagen biofabric
EP1919365A2 (en) *	2005-07-13	2008-05-14	Anthrogenesis Corporation	Ocular plug formed from placenta derived collagen biofabric
EP1919500A2 (en) *	2005-07-13	2008-05-14	Anthrogenesis Corporation	Treatment of leg ulcers using placenta derived collagen biofabric
WO2007011693A2 (en) *	2005-07-14	2007-01-25	Medistem Laboratories, Inc.	Compositions of placentally-derived stem cells for the treatment of cancer
AU2006304277B2 (en) *	2005-10-13	2012-07-05	Celularity Inc.	Immunomodulation using placental stem cells
EP1979050B1 (en) *	2005-12-28	2017-04-19	DePuy Synthes Products, Inc.	Treatment of peripheral vascular disease using postpartum-derived cells
ES2671355T3 (es) *	2005-12-29	2018-06-06	Anthrogenesis Corporation	Poblaciones de células madre placentarias
WO2007146105A2 (en) *	2006-06-05	2007-12-21	Cryo-Cell International, Inc.	Procurement, isolation and cryopreservation of fetal placental cells
US20080050814A1 (en) *	2006-06-05	2008-02-28	Cryo-Cell International, Inc.	Procurement, isolation and cryopreservation of fetal placental cells
WO2007146123A2 (en) *	2006-06-09	2007-12-21	Anthrogenesis Corporation	Placental niche and use thereof to culture stem cells
US20090081171A1 (en) *	2006-08-11	2009-03-26	Yu-Show Fu	Cell system for alleviating syndromes of Parkinson's disease in a mammal
WO2008021391A1 (en) *	2006-08-15	2008-02-21	Anthrogenesis Corporation	Umbilical cord biomaterial for medical use
US20080050347A1 (en) *	2006-08-23	2008-02-28	Ichim Thomas E	Stem cell therapy for cardiac valvular dysfunction
ZA200902233B (en) *	2006-10-23	2010-07-28	Anthrogenesis Corp	Methods and compositions for treatment of bone defects with placental cell populations
EP2129775A1 (en) *	2007-02-12	2009-12-09	Anthrogenesis Corporation	Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
US20090053182A1 (en) *	2007-05-25	2009-02-26	Medistem Laboratories, Inc.	Endometrial stem cells and methods of making and using same
US20090016999A1 (en) *	2007-07-13	2009-01-15	Michael Cohen	Embryonic cell compositions for wound treatment
CA2630708C (en) *	2007-09-13	2017-08-01	Clifford L. Librach	Method of isolation and use of cells derived from first trimester umbilical cord tissue
KR20140107677A (ko) *	2007-09-19	2014-09-04	플루리스템 리미티드	지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도
KR20220122774A (ko) *	2007-09-26	2022-09-02	셀룰래리티 인코포레이티드	인간 태반 관류액으로부터의 혈관형성 세포
DK2330889T3 (en) *	2008-08-20	2017-01-30	Anthrogenesis Corp	Improved cell composition and process for making the same
KR20180108887A (ko) *	2008-08-20	2018-10-04	안트로제네시스 코포레이션	단리된 태반 세포를 사용한 뇌졸중 치료
MX2011001992A (es) *	2008-08-22	2011-03-29	Anthrogenesis Corp	Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
CN201299504Y (zh) *	2008-11-11	2009-09-02	薛华	一种方便搭挂的毛巾
AR077369A1 (es) *	2009-07-02	2011-08-24	Anthrogenesis Corp	Metodopara producir eritrocitos sin celulas alimentadoras
TWI395125B (zh) *	2009-07-14	2013-05-01	Sonix Technology Co Ltd	電容式觸控感應電路

2008
- 2008-09-26 KR KR1020227028466A patent/KR20220122774A/ko not_active Ceased
- 2008-09-26 EP EP08833350A patent/EP2205719A1/en not_active Withdrawn
- 2008-09-26 RU RU2010116271/10A patent/RU2010116271A/ru not_active Application Discontinuation
- 2008-09-26 KR KR1020207033934A patent/KR20200136051A/ko not_active Withdrawn
- 2008-09-26 CA CA2700613A patent/CA2700613C/en active Active
- 2008-09-26 KR KR1020167020487A patent/KR20160092062A/ko not_active Ceased
- 2008-09-26 KR KR1020187015067A patent/KR20180059583A/ko not_active Ceased
- 2008-09-26 CN CN2008801178057A patent/CN101978045A/zh active Pending
- 2008-09-26 KR KR1020197012717A patent/KR20190050867A/ko not_active Ceased
- 2008-09-26 KR KR1020217028887A patent/KR20210118946A/ko not_active Ceased
- 2008-09-26 AU AU2008305516A patent/AU2008305516A1/en not_active Abandoned
- 2008-09-26 BR BRPI0818191A patent/BRPI0818191A8/pt not_active Application Discontinuation
- 2008-09-26 KR KR1020107008970A patent/KR101644659B1/ko not_active Expired - Fee Related
- 2008-09-26 JP JP2010526961A patent/JP5703493B2/ja not_active Expired - Fee Related
- 2008-09-26 MX MX2010003217A patent/MX2010003217A/es not_active Application Discontinuation
- 2008-09-26 KR KR1020157020016A patent/KR101645311B1/ko not_active Expired - Fee Related
- 2008-09-26 KR KR1020207011050A patent/KR20200043517A/ko not_active Withdrawn
- 2008-09-26 US US12/239,679 patent/US20090104164A1/en not_active Abandoned
- 2008-09-26 WO PCT/US2008/011167 patent/WO2009042201A1/en not_active Ceased
2010
- 2010-03-25 IL IL204762A patent/IL204762A0/en active IP Right Grant
2014
- 2014-09-26 JP JP2014196899A patent/JP5985569B2/ja not_active Expired - Fee Related
2015
- 2015-11-17 IL IL242645A patent/IL242645B/en active IP Right Grant
- 2015-11-17 IL IL242644A patent/IL242644B/en active IP Right Grant
2016
- 2016-08-03 JP JP2016152885A patent/JP2017002071A/ja active Pending
2018
- 2018-06-26 IL IL260292A patent/IL260292A/en unknown
- 2018-07-06 JP JP2018129253A patent/JP2018172425A/ja active Pending
2020
- 2020-08-13 JP JP2020136719A patent/JP2020189872A/ja active Pending
2022
- 2022-08-19 JP JP2022131194A patent/JP2022166249A/ja active Pending

Also Published As

Publication number	Publication date
KR20100091160A (ko)	2010-08-18
CA2700613C (en)	2022-09-20
KR20180059583A (ko)	2018-06-04
JP5703493B2 (ja)	2015-04-22
JP5985569B2 (ja)	2016-09-06
IL260292A (en)	2018-07-31
KR20160092062A (ko)	2016-08-03
KR20190050867A (ko)	2019-05-13
JP2018172425A (ja)	2018-11-08
US20090104164A1 (en)	2009-04-23
RU2010116271A (ru)	2011-11-10
KR101645311B1 (ko)	2016-08-03
KR20210118946A (ko)	2021-10-01
KR20150090276A (ko)	2015-08-05
JP2015042648A (ja)	2015-03-05
KR20220122774A (ko)	2022-09-02
JP2022166249A (ja)	2022-11-01
JP2010540530A (ja)	2010-12-24
KR20200136051A (ko)	2020-12-04
CN101978045A (zh)	2011-02-16
KR20200043517A (ko)	2020-04-27
AU2008305516A1 (en)	2009-04-02
WO2009042201A1 (en)	2009-04-02
KR101644659B1 (ko)	2016-08-01
JP2017002071A (ja)	2017-01-05
JP2020189872A (ja)	2020-11-26
CA2700613A1 (en)	2009-04-02
IL242645B (en)	2018-07-31
IL204762A0 (en)	2010-12-30
MX2010003217A (es)	2010-07-30
IL242644B (en)	2018-07-31
BRPI0818191A8 (pt)	2017-10-03
EP2205719A1 (en)	2010-07-14

Legal Events

Date	Code	Title	Description
2017-10-03	B25D	Requested change of name of applicant approved	Owner name: ANTHROGENESIS CORP. (US)
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-06-05	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-06-12	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-07-31	B07B	Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
2019-10-15	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-12-24	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-05-26	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-10-20	B09B	Patent application refused [chapter 9.2 patent gazette]
2021-01-05	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

Publication	Publication Date	Title
BRPI0818191A2 (pt)	2017-06-13	métodos para a formação de vasos a partir de uma população de células de perfusato placentário e para o tratamento de um indivíduo tendo uma doença cardíaca ou vascular, distúrbio, condição ou insulficência
BR112013021125A2 (pt)	2019-09-24	método para regular os níveis de glicose no sangue, método para aumentar a secreção da insulina ou promover a liberação da insulina na corrente sanguínea, método para tratar uma doença ou condição, método para retardar o ínicio de uma doença ou condição de doença kit, composto de composição farmacêutica
ZA200900788B (en)	2011-05-25	Manufacture,method,and use of active substance-releasing medical products for permanently keeping blood vessels open
BRPI0910198A2 (pt)	2016-01-12	composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.
BR112012024267A2 (pt)	2017-12-19	dispositivo médico, conjunto, procedimento médico, método para permanentemente intensificar a circulação sanguínea intracardíaca de um coração de um paciente e meio de leitura
BRPI0817925A2 (pt)	2015-04-07	Sistema e método para monitorar e regular níveis de glicose no sangue em uma corrente sanguiínea
IL220318A (en)	2015-10-29	Aqueous solutions comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart diseases
WO2009100137A3 (en)	2009-10-01	Magnetic cells for localizing delivery and tissue repair
BRPI1011760A2 (pt)	2015-10-06	método para prevenir ou reduzir coagulação no trato gastrointestinal superior de um indivíduo, e, uso de proteína anticoagulante.
EP1740178A4 (en)	2007-09-19	METHODS AND COMPOSITIONS FOR THE TREATMENT, PREVENTION OR MANAGEMENT OF SLEEP DISORDERS AND SLEEP DISORDERS ASSOCIATED WITH A DISEASE
EP2068702A4 (en)	2012-10-17	SYSTEM AND TECHNIQUES BASED ON PULSE OXYMETER FOR DERIVING CARDIAC AND RESPIRATORY PARAMETERS FROM EXTRA-THORACIC BLOOD FLOW MEASUREMENTS
BR112012003462A2 (pt)	2016-02-23	"composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
FR2939643B1 (fr)	2012-12-14	Dispositif pulsatile et non invasif d'assistance circulatoire et hemodynamique.
WO2012007839A3 (en)	2012-04-26	Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
EP4374860A3 (en)	2024-08-07	Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EP2478901A3 (en)	2012-11-14	Neurogenic compounds
BRPI0920170A2 (pt)	2016-06-21	métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
EP2716285A3 (en)	2014-09-03	New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
BRPI0908872A2 (pt)	2015-11-24	composto, composição farmacêutica, uso do composto, e, método para tratar, prevenir ou aliviar uma doença ou um distúrbio ou uma condição de um corpo de animal vivo
EP1838260A4 (en)	2011-05-25	SYSTEM AND METHOD FOR TREATMENT OF CARDIAC TISSUE
WO2009007112A3 (en)	2009-04-16	Thrombomodulin for increasing reperfusion and preventing blood vessels obstruction
BRPI0817710A2 (pt)	2015-03-31	Sistema e método para monitorar e regular níveis de glicose no sangue em uma corrente sanguínea
RU2005104170A (ru)	2006-07-27	Способ проведения склеропластической операции
WO2006113220A3 (en)	2007-01-18	Transgenic mammals expressing human preproinsulin
WO2007021933A3 (en)	2007-07-12	Methods and compositions for use in treating vascular diseases and conditions